LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that it has continued to build its patent portfolio with the issuance of three key patents for its Simoa platform.
Two of the patents, which are at the foundation of the Simoa technology, are assigned to Tufts University and exclusively licensed to Quanterix. The third patent is a result of Quanterix’s own innovation, which takes the Simoa technology a step further by combining digital and analog signal measurements, allowing a broad dynamic range of concentrations that can be measured. The result enables the detection and quantification of biomarkers previously difficult or impossible to measure.
"This milestone highlights the achievements of our scientific team for developing a truly novel approach to single molecule immunoassays," said Paul Chapman, President and CEO of Quanterix. "These new patents demonstrate the remarkable innovation at the core of our Simoa technology, which provides researchers with the ability to detect biomarkers at concentrations 1000 times lower than possible today. This in turn opens up new applications to address significant unmet needs in life science research, biopharma, and in-vitro diagnostics."
About Quanterix
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
